Caribou Biosciences

Berkeley, United States Founded: 2011 • Age: 15 yrs Listed
Provider of cell therapies to treat cancer and hematologic conditions

About Caribou Biosciences

Caribou Biosciences is a publicly listed company based in Berkeley (United States) founded in 2011 by Jennifer Doudna, James Berger, and Martin Jinek. Provider of cell therapies to treat cancer and hematologic conditions. Caribou Biosciences has raised $156.55 million across 6 funding rounds from investors including AbbVie, Pfizer and Novartis. The company has 147 employees. Its website cariboubio.com draws about 10 thousand monthly visits. Caribou Biosciences offers products and services including chRDNA Technology and CAR-T Cell Therapies. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Caribou Biosciences, Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.

Company details

Caribou Biosciences was founded in 2011 in Berkeley, United States, within the biotechnology sector. Cellular engineering and analysis solutions are developed based on CRISPR-Cas9 biology. These tools are applied across therapeutics, agricultural biotechnology, biological research, and industrial biotechnology. CAR-T cell therapies for non-Hodgkin lymphoma and myeloid leukemia have been created, as have iPSC-derived CAR-NK therapies targeting solid tumors. Operations focus on advancing treatments for hematologic and oncologic conditions.

  • Headquarters Berkeley, United States
  • Employees 147
  • Founders Jennifer Doudna, James Berger, Martin Jinek
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website cariboubio.com
  • Social LinkedIn X
  • Legal Name Caribou Biosciences, Inc.
Key Metrics
  • Annual Revenue
    $11.16 M (USD)
    11.66
    as on Dec 31, 2025
  • Net Profit
    -$148.13 M (USD)
    0.66
    as on Dec 31, 2025
  • EBITDA
    -$132.55 M (USD)
    18.53
    as on Dec 31, 2025
  • Total Equity Funding
    $156.55M (USD)

    in 6 rounds

  • Latest Funding Round
    $25M (USD), Post-IPO

    Jun 2023

  • Investors
    AbbVie

    & 24 more

  • Employee Count
    147

Products & Services of Caribou Biosciences

Caribou Biosciences offers a comprehensive portfolio of products and services, including chRDNA Technology and CAR-T Cell Therapies.

chRDNA Technology
Genome Editing Tool

Enables precise CRISPR-based editing for gene knockout and insertion.

CAR-T Cell Therapies
Cell Therapy Product

Develops off-the-shelf treatments for hematologic malignancies and diseases.

Funding Insights of Caribou Biosciences

Caribou Biosciences has successfully raised a total of $156.55M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $156.55M
  • Total Rounds 6
  • Last Round Post-IPO β€” $25M
  • First Round $158,902

    (May 2013)

  • Investors Count 25

All 6 funding rounds of Caribou Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2023$25MPost-IPO––
Mar 2021$115MSeries C–Farallon Capital Management, Ridgeback Capital Management
May 2016$30MSeries B–Anterra Capital, Heritage Group
Mar 2015$11.55MSeries A––
Jul 2013$150,000Grant––
May 2013$158,902Grant––
Valuation history

25 investors in total: 25 institutional.

Investors in Caribou Biosciences

Caribou Biosciences has secured backing from 25 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Pfizer and Novartis.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Multiple investment strategies are pursued by this hedge fund.
1986faralloncapital.comSan Francisco, United States
Ridgeback Capital is focused on healthcare and life science investments.
ridgebackcap.comNew York, United States
Early-stage tech and life-sciences firms are funded across the US.
maverickventures.comSan Francisco, United States
Healthcare startups are funded by this corporate-backed venture capital entity.
lifesciventure.comNew York, United States
Long-term private equity investments in transformational opportunities are pursued.
invus.comNew York, United States
Multiple sectors are targeted for venture capital investments.
1934janushenderson.comLondon, United Kingdom
Venture capital firm focused on multiple sectors
Dallas, United States
Private equity investments are directed toward the healthcare sector.
avego.comAlpharetta, United States
Aliment Capital is focused on sustainable food system investments.
alimentcap.comLos Angeles, United States
Tech focused growth stage VC firm investing in Europe & North America
2012anterracapital.comAmsterdam, Netherlands
Premium access

Investor details for Caribou Biosciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Caribou Biosciences

65 people are tracked at Caribou Biosciences (36 in leadership, 15 in board & advisors, 14 in team); the tracked headcount is 147.

NameRoleGroup
Jennifer Doudna
Co-FounderLeadership
James Berger
Co-FounderLeadership
Martin Jinek
Co-FounderLeadership
Ruhi Khan
Chief Business OfficerLeadership
Maryam Sorkhabi
Sr. Director, External Manufacturing OperationsLeadership
Barbara Mcclung
Chief Legal Officer & Corporate SecretaryLeadership
Sri Ryali
Chief Financial OfficerLeadership
Rodolfo Gonzalez
Executive Director, Stem Cell TherapeuticsLeadership
Chris Holland
Head Of BiometricsLeadership
Eddie Ruelas
Director Of IT ApplicationsLeadership
Garima Baloria
Director, Regulatory Affairs CMCLeadership
Karen Lyle
Senior DirectorLeadership
Madison Kuchta
Director Of Financial Planning And AnalysisLeadership
Elaine Alambra
VP, Regulatory Affairs & Quality AssuranceLeadership
Cindy Hayashi
VP, HRLeadership
Alexandra Lied
Associate Director Of Program ManagementLeadership
Eric Stawiski
Vice President Of BioinformaticsLeadership
Ryan Fischesser
VP, Finance & ControllerLeadership
Justin Skoble
VP, Technical OperationsLeadership
Elizabeth Garner
Executive Director Of T Cell Therapeutics And Translational Sciences LaboratoryLeadership

45 more people are available in the full profile.

Premium access

Complete people profiles for Caribou Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Caribou Biosciences

Caribou Biosciences is a publicly listed company on the NASDAQ with ticker symbol CRBU in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date23 Jul 2021
  • Listed onNASDAQ: CRBU
  • Listed entityCaribou Biosciences, Inc.
  • Exchange sectorHealth technology
  • ISINUS1420381089
  • Share price$0.47 (-5.41% on the day) · 2026-10-13
  • Market capitalisation$50.4M
  • EPS (diluted, trailing year)$-1.08
  • Volume (last session)4,546,001

Financials of Caribou Biosciences

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$11.2M-$148.1M-$132.6M
2024$10.0M-$149.1M-$162.7M
2023$34.5M-$102.1M-$112.5M
2022$13.8M-$99.4M-$102.8M
2021$9.6M-$66.9M-$66.0M
Premium access

Detailed financial statements for Caribou Biosciences

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Caribou Biosciences

4 dated milestones of Caribou Biosciences across 12 years, from founding to its latest funding, stage changes and deals.

  1. Founded Caribou Biosciences is founded.
  2. Funding First funding round of $159K.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $25.0M.

Competitors of Caribou Biosciences

Caribou Biosciences has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
bridgebio.com2015Palo Alto, United States$434.2M
Therapeutics for genetic diseases are developed through targeted interventions.
sparktx.com2013Philadelphia, United States$82.8M822
Gene therapies for rare diseases including retinal dystrophies are developed.
alnylam.com2002Cambridge, United States$17M2,100
RNA interference-based therapeutics are developed for multiple disorders.
Premium access

Detailed competitors of Caribou Biosciences

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Caribou Biosciences

The website of Caribou Biosciences (cariboubio.com) receives about 10.3K visits a month.

  • Monthly visits
    10.3K

    ▼ 25.9% vs previous month

Similar websites

Websites whose visitors overlap most with Caribou Biosciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
andelynbio.com
100%
7.1K#2,697,524View details

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Caribou Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Caribou Biosciences

Premium access

Complete news archive for Caribou Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Caribou Biosciences

Caribou Biosciences was founded in 2011 and raised its 1st funding round 2 years after it was founded.

Caribou Biosciences is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.

Caribou Biosciences is a funded company, having raised a total of $156.55M across 6 funding rounds to date. The company's 1st funding round was a Grant of $158.9K, raised on May 2013.

Caribou Biosciences has 147 employees.

Annual revenue of Caribou Biosciences is $11.16M as on Dec 31, 2025.

Caribou Biosciences was founded in 2011 in Berkeley, United States, within the biotechnology sector. Cellular engineering and analysis solutions are developed based on CRISPR-Cas9 biology. These tools are applied across therapeutics, agricultural biotechnology, biological research, and industrial biotechnology. CAR-T cell therapies for non-Hodgkin lymphoma and myeloid leukemia have been created, as have iPSC-derived CAR-NK therapies targeting solid tumors. Operations focus on advancing treatments for hematologic and oncologic conditions.

Caribou Biosciences's top competitors include Spark Therapeutics, BridgeBio and Alnylam.

Caribou Biosciences offers chRDNA Technology and CAR-T Cell Therapies.

Yes, Caribou Biosciences is publicly traded on NASDAQ under the ticker symbol CRBU.

Caribou Biosciences has 25 investors. Key investors include AbbVie, Pfizer, Novartis, Janus Henderson Investors, and Farallon Capital Management.

Caribou Biosciences operates through Caribou Biosciences, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available